References (47)

1. Walsh FM, Amyes SGB: Microbiology and drug resistance mechanisms of fully resistant pathogens. Curr Opin Microbiol 2004, 7, 439–444.
2. Breithaupt H: The new antibiotics. Nat Biotechnol 1999, 17, 1165–1169.
3. Merril CR, Scholl D, Adhya SL: The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2003, 2, 489–497.
4. Thiel K: Old dogma, new tricks – 21st century phage therapy. Nat Biotechnol 2004, 22, 31–36.
5. Lorch A: Bacteriophages: an alternative to antibiotics? Biotechnol Dev Monitor 1999, 39, 14–17.
6. Debattista J: Phage therapy: where East meets West. Expert Rev Anti Infect Ther 2004, 2, 815–819.
7. Sulakvelidze A, Alavidze Z, Glenn Morris J Jr.: Bacteriophage therapy. Antimicrob Agents Chemother 2001, 45, 649–659.
8. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR: Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin−resistant Enterococcus faecium. Infect Immun 2002, 70, 204–210.
9. Carlton R: Phage therapy: past history and future prospects. Arch Immunol Ther Exp 1999, 47, 267–274.
10. Schoolnik GK, Summers WC, Watson JD: Phage offer a real alternative. Nat Biotechnol 2004, 22, 505–506.
11. Campbell A: The future of bacteriophage biology. Nat Rev Gen 2003, 4, 471–477.
12. Smith HW, Huggins MB: Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982, 128, 307–318.
13. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, Li QQ, Hu J: Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem−resistant Pseudomonas aeruginosa. Int J Mol Med 2006, 17, 309–317.
14. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, Gong J, Li QQ, Hu J: Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta−lactamase−producing Escherichia coli bacteremia. Int J Mol Med 2006, 17, 347–355.
15. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Shigeyoshi S, Sugiura T, Koda S, Muraoka A, Imai S: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage ØMR11. J Inf Dis 2003, 187, 613–624.
16. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Norris JS: Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 2003, 47, 1301–1307.
17. Sulakvelidze A: Phage therapy: an attractive option for dealing with antibiotic−resistant bacterial infections. Drug Discov Today 2005, 10, 807–809.
18. Carlton RM, Noordman WH, Biswas B, de Meester ED, Loessner MJ: Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Reg Toxicol Pharmacol 2005, 43, 301–312.
19. Boratynski J, Syper D, Weber−Dabrowska B, Lusiak−Grzelachowska M, Pozniak G, Gorski A: Preparation of endotoxin−free bacteriophages. Cell Mol Biol Lett 2004, 9, 253–259.
20. Merril C, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S: Long−circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 1996, 93, 3188–3192.
21. Veronese FM, Pasut G: PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10, 1451–1458.
22. Comeau AM, Krisch HM: War is peace: dispatches from the bacterial and phage killing fields. Curr Opin Microbiol 2005, 8, 488–494.
23. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, Unno H: Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 2005, 100, 280–287.
24. Barrow PA, Soothill JS: Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 1997, 5, 268–271.
25. Duckworth DH, Gulig PA: Bacteriophages. Potential treatment for bacterial infections. Biodrugs 2002, 16, 57–62.
26. Summers WC: Bacteriophage therapy. Annu Rev Microbiol 2001, 55, 437–451.
27. Alisky J, Iczkowski K, Rapoport A, Troitsky N: Bacteriophage show promise as antimicrobial agents. J Infect 1998, 36, 5–15.
28. Bradbury J: My enemy’s enemy is my friend. Using phages to fight bacteria. Lancet 2004, 363, 624–625.
29. Parfitt T: Georgia: an unlikely stronghold for bacteriophage therapy. Lancet 2005, 365, 2166–2167.
30. Thacker PD: Set a microbe to kill a microbe. Drug resistance renews interest in phage therapy. J Am Med Assoc 2003, 290, 3183–3185.
31. Stone R: Stalin’s forgotten cure. Science 2002, 298, 728–731.
32. Levin BR, Bull JJ: Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2004, 2, 166–173.
33. Weber−Dabrowska B, Mulczyk M, Gorski A: Bacteriophage therapy of bacterial infections: an update of our Institute’s experience. Arch Immunol Ther Exp 2000, 48, 547–551.
34. Bruttin A, Brussow H: Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005, 49, 2874–2878.
35. Miedzybrodzki R, Fortuna W, Weber−Dabrowska B, Gorski A: Bacterial viruses against viruses pathogenic for man? Virus Res 2005, 110, 1–8.
36. Krichevsky A, Rusnati M, Bugatti A, Waigmann E, Shokat S, Loyter A: The fd phage and a peptide derived from its p8 coat protein interact with the HIV−1 Tat−NLS and inhibits its biological functions. Antiviral Res 2005, 66, 67–78.
37. Clark JR, March JB: Bacterial viruses as human vaccines? Expert Rev Vaccines 2004, 3, 463–476.
38. Gorski A, Nowaczyk M, Weber−Dabrowska B, Kniotek M, Boratynski J, Ahmed A, Dabrowska K, Wierzbicki P, Switala−Jelen K, Opolski A: New insights into the possible role of bacteriophages in transplantation. Transplant Proc 2003, 35, 2372–2373.
39. Gorski A, Kniotek M, Perkowska−Ptasinska A, Mroz A, Przerwa A, Gorczyca W, Dabrowska K, Weber−Dabrowska B, Nowaczyk M: Bacteriophages and transplantation tolerance. Transplant Proc 2006 38, 331–333.
40. Nelson D, Loomis L, Fischetti VA: Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001, 98, 4107–4112.
41. Fischetti VA: Bacteriophage lytic enzymes: novel anti−infectives. Trends Microbiol 2005, 13, 491–496.
42. Borysowski J, Weber−Dabrowska B, Gorski A: Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med 2006, 231, 366–377.
43. Fischetti VA: Novel method to control pathogenic bacteria on human mucous membranes. Ann N Y Acad Sci 2003, 987, 207–214.
44. Loeffler J, Nelson D, Fischetti VA: Rapid killing of Streptococcus pneumoniae with a bacteriophage hydrolase. Science 2001, 294, 2170–2172.
45. Cheng Q, Nelson D, Zhu S, Fischetti VA: Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 2005, 49, 111–117.
46. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P: Phage lytic enzymes as therapy for antibiotic−resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003, 52, 967–973.
47. Loeffler J, Djurkovic S, Fischetti VA: Phage lytic enzyme Cpl−1 as a novel antimicrobial for pneumococcal bacteremia. Inf Immun 2003, 71, 6199–6204.